Astellas Pharma Inc. and Seattle Genetics Inc. announced data from the first cohort of a pivotal phase II clinical trial known as EV-201 demonstrated the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44% (55/125; 95% Confidence Interval: 35.1-53.2).
A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective, new therapy for people with a specific type of advanced melanoma.
Taiho Oncology Inc. and Servier announced clinical data with Lonsurf (trifluridine and tipiracil, TAS-102) in previously treated patients with metastatic gastric cancer, metastatic gastroesophageal junction adenocarcinoma, and metastatic colorectal cancer were presented at the 2019 ASCO Annual Meeting.
Early-onset colorectal cancer is rising most rapidly in Western states, where healthy behaviors are prominent, according to a new study from the American Cancer Society and Ohio State University. The authors of the study, which appears in JNCI, say the findings indicate the need for further etiologic studies to explore early-life colorectal carcinogenesis.
Researchers at the Johns Hopkins Kimmel Cancer Center have developed a blood test that can detect the presence of seven different types of cancer by spotting unique patterns in the fragmentation of DNA shed from cancer cells and circulating in the bloodstream.
New research from the Abramson Cancer Center at the University of Pennsylvania, published in the May 2019 issue of the Journal of the National Comprehensive Cancer Network uses a large, real-world dataset to demonstrate there is a modest but consistent survival benefit associated with adding bevacizumab to carboplatin-pemetrexed when treating advanced non-squamous non-small cell lung cancer.
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial.
A new study examining Medicaid expansion and cancer screening found the five states and the District of Columbia that first adopted Medicaid expansion saw larger increases in colorectal cancer screening than states that did not expand Medicaid.
At a press briefing May 16, the American Society of Clinical Oncology announced the following studies will be presented at the 2019 ASCO Annual Meeting in Chicago:
A global phase III ClarIDHy trial of Tibsovo (ivosidenib), sponsored by Agios Pharmaceuticals Inc., in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation met its primary endpoint.
